Company to begin limited market release in Europe in June
MARLBOROUGH, Mass.,
May 25, 2021 /PRNewswire/
-- Boston Scientific Corporation (NYSE: BSX) today announced
it has completed CE Mark for the EXALT™ Model B Single-Use
Bronchoscope, a single-use device designed for bedside procedures
in the intensive care unit, operating room and bronchoscopy suite.
Limited market release of the device is expected to commence in
Europe in the coming weeks.
The EXALT Model B Bronchoscope will be offered in three sizes –
slim, regular and large – to allow for use in a wide variety of
bronchoscopy procedures such as secretion management, airway
intubation, percutaneous tracheostomy, double lumen endotracheal
tube placement and biopsies.
"As single-use bronchoscopes are relatively new, continued
innovation is necessary to ensure physicians can achieve direct and
precise visualization into a patient's lungs and air passages,"
said Prof. Dr. Kaid Darwiche, head
of the Department of Interventional Pneumology at Ruhrlandklinik in
Germany. "The EXALT Model B
Bronchoscope provides clear, crisp imaging and high-powered suction
– both of which are critical to successfully identify any
abnormalities in the patient's airway."
Throughout Europe, more than
1.5 million procedures involving a bronchoscope are performed each
year.i While the potential for infection due to
reprocessing of reusable scopes is low, there have been reports of
scope-associated contaminations and post-procedure
infections.ii To combat this risk, a recent position
statement from the European Society of Gastrointestinal Endoscopy
(ESGE) and the European Society of Gastroenterology Nurses and
Associates (ESGENA) strongly recommended the use of single-use
endoscopic accessories whenever possible.iii
"Single-use scopes are emerging as the preference for many
physicians due to their ability to eliminate the risk of
scope-related infection that may result from ineffective
reprocessing while also increasing operational efficiencies in the
hospital setting," said Dave Pierce,
executive vice president and president of MedSurg and president of
Endoscopy, Boston Scientific. "Innovation is central to our
mission, and the EXALT Model B Bronchoscope is designed to provide
physicians with the high-quality functionality and feel of a
reusable scope, while addressing heightened patient safety needs
and improving efficiency."
The EXALT Model B Bronchoscope is the latest device in the
Boston Scientific single-use imaging portfolio. For decades, the
company has worked closely with physicians to continuously innovate
and develop single-use technologies within the gastrointestinal,
pancreaticobiliary, surgical, urological and airway spaces to
advance patient care, including the EXALT™ Model D Single-Use
Duodenoscope, LithoVue™ Digital Flexible
Ureteroscope, SpyGlass™ DS Direct Visualization
System and SpyGlass™ Discover Digital Catheter.
Please
visit www.bostonscientific.com/en-eu/medical-specialties/pulmonology/exalt-b.html
for more information about the EXALT Model B Bronchoscope.
The EXALT Model B Bronchoscope is not available for use or sale
in the United States.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology leader
for more than 40 years, we advance science for life by providing a
broad range of high performance solutions that address unmet
patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect
on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of
1934. Forward-looking statements may be identified by words
like "anticipate," "expect," "project," "believe," "plan,"
"estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates
using information available to us at the time and are not intended
to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding our business plans, clinical trials, product launches and
product performance and impact. If our underlying assumptions
turn out to be incorrect, or if certain risks or uncertainties
materialize, actual results could vary materially from the
expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases,
have affected and in the future (together with other factors) could
affect our ability to implement our business strategy and may cause
actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result,
readers are cautioned not to place undue reliance on any of our
forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All
of these factors are difficult or impossible to predict accurately
and many of them are beyond our control. For a further list
and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item 1A – Risk Factors in our most recent Annual Report on Form
10-K filed with the Securities and Exchange Commission, which we
may update in Part II, Item 1A – Risk Factors in Quarterly Reports
on Form 10-Q we have filed or will file hereafter. We
disclaim any intention or obligation to publicly update or revise
any forward-looking statements to reflect any change in our
expectations or in events, conditions or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements. This cautionary statement is
applicable to all forward-looking statements contained in this
document.
CONTACTS:
Francesca Cardarelli
Media Relations, EMEA
+39 340 662 6364
Francesca.Cardarelli@bsci.com
Kirsten Lesak-Greenberg
Media Relations, U.S.
+1 (763) 300-9254
Kirsten.Lesak-Greenberg@bsci.com
Susie Lisa, CFA
Investor Relations
(508) 683-5670
BSXInvestorRelations@bsci.com
|
|
|
i Data on file at
Boston Scientific Corporation. Market research is as of 2019 and
includes projections for 2020, incorporating estimates for the
COVID-19 pandemic.
|
ii Mehta A,
Muscarella L. Bronchoscope-related "superbug" infections. CHEST
Journal. 2019; 157(2).
DOI:https://doi.org/10.1016/j.chest.2019.08.003
|
iii Beilenhoff Ulrike
et al. Reprocessing in GI endoscopy: ESGE–ESGENA Position Statement
– Update 2018, Endoscopy 2018; 50
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/boston-scientific-completes-ce-mark-for-exalt-model-b-single-use-bronchoscope-301298633.html
SOURCE Boston Scientific Corporation